



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

### ESPS Peer-review Report

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 2165

**Title:** Roles of ABCG2 expression driven by cisplatin in the efficacy of platinum-contained gastric cancer chemotherapy

**Reviewer code:** 00039017

**Science editor:** Zhai, Huan-Huan

**Date sent for review:** 2013-02-05 15:27

**Date reviewed:** 2013-02-25 15:40

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

The authors report ABCG2 mRNA increased times driven by cisplatin in vitro is associated with a clinical outcome, which may be a novel biological marker for optimizing the treatment of gastric cancer. The focus of this paper is novel and interesting. However, there are several uncertain points in the manuscript, in particular the surgical treatment and the second line chemotherapy need to be more clearly described. 1. The authors describe the tumor tissue obtained from surgically resected specimens, please describe about the surgical procedures and the rate of palliative operation. 2. The patients received platinum-based regimens, how were patients allocated into five regimens? 3. There seemed to no difference in the survival curves until 6 months, how were patients treated after the appearance of progressive disease. Please describe second line regimens. 4. ABCG2 has been reported to play an active role in multidrug resistance in various cancers. Please describe the time to progression by the first-line chemotherapy according to ABCG2 mRNA increased times.